An infectious raccoon poxvirus (RCNV) was used to express the feline panleukopenia virus (FPV) open reading frame VP2. The recombinant, RCNV/FPV, was constructed by homologous recombination with a chimeric plasmid for inserting the expression cassette into the thymidine kinase (TK) locus of RCNV. Expression of the VP2 DNA was regulated by the vaccinia virus late promoter P 11 . Southern blot and polymerase chain reaction (PCR) analyses confirmed the cassette was in the TK gene of the RCNV genome. An immunofluorescent antibody assay using feline anti-FPV polyclonal serum showed the expressed viral antigen in the cytoplasm of infected cells. Radioimmunoprecipitation with the same antiserum detected a 67-kDa VP2 protein which exactly matched the migration of the authentic FPV VP2 protein by SDS-polyacrylamide gel electrophoresis. Nine five-month-old cats were vaccinated and 21 days later were boosted with the recombinant virus. Peroral FPV challenge 2 weeks after the booster showed that the cats were fully protected as measured by examining clinical signs and total white blood cell counts in peripheral blood. Cats not immunized developed low to very low leukocyte counts following peroral FPV challenge. The nine vaccinated cats showed high FPV neutralization antibody prior to challenge, whereas nonvaccinated cats formed anti-FPV antibodies only after challenge. ᭧
Feline panleukopenia virus (FPV) causes severe clinical
VP2 protein which is converted to a 60-to 64-kDa polypeptide (VP3) by proteolytic cleavage to remove 15 to 20 illness in young kittens with high morbidity and mortality amino acids. Empty viral particles propagated in vitro or (1) (2) (3) . Because the replication of FPV requires rapidly multiin vivo contain mostly VP2, a few VP1 subunits, and no plying cells, the lesions caused by FPV are mainly found VP3 (9, 10). Intact virions contain the three proteins in tissues with the greatest rate of mitotic activity, such as nested to include the viral DNA (11, 12) . Infectious CPV in bone marrow (1, 2) . Clinically, a marked drop in total particles contain 60 subunits of protein that is predomileukocyte count by Days 4 to 6 after infection is the predomnantly VP2. inant indicator of FPV infection (2) (3) (4) .
Structure analysis of CPV particles has revealed that FPV is closely related to canine parvovirus (CPV) and part of the amino terminal region of VP2 is on the exterior mink enteritis virus at the protein and nucleic acid levels of the virion and is associated with immunodominant (5, 6) . The complete genomic DNA sequences of FPV antigenic epitopes (13). Certain residues on the extreme and CPV have been determined. The sequences reveal outside of the CPV particles are in common with residues that there are only 50 nucleotide differences between on FPV particles (13). Because the amino terminal of VP1 the two viruses (7) . The host range differences between is unusually basic, it might help neutralize the DNA (14). the two viruses were found in the DNA region of 59-73 Antisera against FPV and CPV have shown very similar map units (7, 8) . The genome of FPV is a linear, singleantibody titers against either virus by virus neutralization stranded DNA of about 5,000 nucleotides that encodes (VN) and hemagglutination-inhibition tests (5, 8, 15) . three structural proteins: a large 80-to 85-kDa protein Based on the close similarities between CPV and FPV, (VP1) composing 10 to 15% of the virion protein, a meit has been speculated that the vaccines developed with dium size 64-to 67-kDa protein (VP2), and a part of the either virus will protect against both feline and canine parvovirus infections (16). Finally, the structural proteins, VP1 and VP2 of Aleutian mink disease parvovirus (ADV), Raccoon poxvirus (RCNV) is an orthopoxvirus; two iso-cleotides 516-535) and GATCACCATCTGCTGGTTGA (VP2 ORF nucleotides 1627-1608) were utilized to iden-lates were derived from upper respiratory tissue of two apparently healthy raccoons trapped in Maryland in 1964 tify satisfactory recombinant viral plaques. The VP2 ORF sequences were detected in lysates of virus-infected (18). A comparative study with several different poxviruses has indicated that RCNV inoculation of cats induces higher cells by dot-blot hybridizations, and in recombinant viral genome DNA by detecting PCR amplified VP2 ORF inter-autologous VN antibody titer than autologous antibodies induced by other poxviruses tested (19). Laboratory animal nal sequences in thrice plaque-purified, phenol-chloroform-extracted, recombinant viral genome DNA prepara-studies with a RCNV rabies virus glycoprotein recombinant (RCN-G) have indicated that oral administration of RCN-G tions (data not shown). The recombinant virus isolate replicated in Rat-2 cells under BUDR and formed typical induces rabies VN antibodies and protection against rabies challenge in raccoons and in a variety of other animals RCNV plaques. The results suggested to us that the inserted VP2 ORF was located in the TK locus of the RCNV tested (20). In cats vaccinated perorally, RCN-G has been genome. Production of the recombinant virus confirmed shown to induce rabies virus VN antibodies and not spread also that VV TK insertion vectors such as pTKgptF3S can to cats in contact with vaccinated cats (16). Earlier, it had be directly used for foreign gene insertion into the RCNV been shown that the thymidine kinase (TK) gene fragment TK locus (20, 21). of RCNV was able to cross-hybridize with that of vaccinia virus (VV), and this enabled construction of RCNV recombi-
The in vitro expression of VP2 protein by recombinant RCNV/FPV was demonstrated by indirect immunofluores-nants with various chimeric plasmids designed for foreign gene expression by marker rescue into the VV TK locus cent antibody (IIFA) and radioimmunoprecipitation (RIP) tests as shown in Figs. 1 and 2. In the IIFA test, RCNV-(20-22).
infected CrFK cells ( Fig. 1a ) and mock-infected CrFK cells In the present study, an infectious RCNV FPV VP2 re-(not shown) did not react with anti-FPV antibodies. FPVcombinant (RCNV/FPV) was developed by recombining infected CrFK cells showed intranuclear fluorescence a FPV VP2 expression cassette into the TK locus of the ( Fig. 1b) ; however, RCNV/FPV-infected CrFK cell mono-RCNV genome. To generate the recombinant, the FPV layers showed VP2 antigen in the cytoplasm (Fig. 1c ). VP2 open reading frame (ORF) in 2304 bp excised from
The FPV polyclonal antiserum used in our experiments a FPV infectious clone was inserted into the plasmid is a standard diagnostic serum that does not cross-react pTKgptF3S (23). The first 33 bases of the ORF were dewith RCNV or feline viruses generally tested for in veterileted by HincII digestion and the remaining DNA fragnary clinics. ment was inserted under control of the VV P 11 late promoter in pTKgptF3S. Southern blot analysis followed by
The infection and replication cycle of orthopoxviruses, including raccoon poxvirus, occurs completely in the cy-sequencing with a CTACTTGCATAGATAGGT primer, designed to anneal 167 bases up from a start codon at the toplasm (27) . Consistent with this, the VP2 protein expressed by RCNV/FPV under promoter P 11 appears in end of the P 11 late promoter, enabled selection of an appropriate chimeric plasmid (not shown) for developing the cytoplasm during the late infection stage. Interestingly, ADV structural proteins VP1 and VP2 coexpressed recombinant RCNV. Thus, pTKgptF3S containing the leftend of the VV TK followed by TAAAAATATAGTAGAATT-in a baculovirus expression system have been shown to be empty particles in the nucleus of baculovirus recombi-TCATTTTGTTTTTTTCTATGCTATAAATGAATTCCTGC-AGGTCAACCTGCTGTCA and the remainder of VP2 nant-infected insect cells (17). During authentic FPV infection, VP1 and VP2 also appear in the nucleus, mainly sequences to the stop codon was selected for further analysis (note: nucleotides to the left of the ATG (bold in virus particles. Because we expressed only FPV VP2, we did not examine RCNV/FPV-infected cells for empty font) are P 11 late promoter sequences; nucleotides to the right of the ATG are the in-frame bases of the VP2 ORF FPV particles. The reason why the VP2 transcription product in RCNV/FPV-infected cells is not transported to from a HincII site in a polylinker sequence that remained after cloning).
the nucleus is unclear. However, the marked shut down of host cell protein synthesis by the late time of RCNV/ Infectious RCNV recombinants carrying the VP2 ORF FPV infection and/or lack of other coexpressed FPV comwere obtained by transfecting the chimeric plasmid into ponents, e.g., VP1, might be responsible. CV-1 cell monolayers that had been infected for 2 hr with RCNV by methods described elsewhere (20, 22, (24) (25) (26) .
RIP of [ 35 S]methionine pulse-labeled proteins in lysates of cells infected with RCNV/FPV or RCNV also Rat-2 TK minus cells were then used to select RCNV recombinant viruses by thrice plaque-purifying in the showed that VP2 protein is expressed by RCNV/FPV and that VP2 is recognized by FPV antibodies (Fig. 2) . Four presence of 50 mg 5-bromo-2-deoxyuridine (BUDR)/ml of medium. Dot-blot hybridizations with a VP2 DNA probe plaque-purified RCNV/FPV recombinant preparations that we made expressed VP2 protein when examined by and PCR amplifications of VP2 ORF internal sequences with primers AGTTCAACCAGACGGTGGTC (VP2 ORF nu-8 to 25% gradient gel SDS-PAGE. The expressed protein migrated at 67 kDa (lanes 1-4) , which is the same as reported (9, 10, 13) for mature VP2 protein from FPVinfected cells. The 67-kDa protein did not appear in lysates of cells infected with RCNV (lane 5) or mock-infected cell lysates (not shown). Specific recognition of VP2 protein by FPV polyclonal antiserum in IIFA and RIP assays suggested to us that FIG. 2. Radioimmunoprecipitation detection of FPV VP2 expressed by RCNV/FPV. CV-1 cell monolayers were infected with the RCNV/FPV or RCNV and then incubated at 37Њ for 1 hr in methionine-free medium followed by pulse-labeling for 16 hr at 37Њ in medium containing 500 mCi [ 35 S]methionine. The cells were washed and then lysed in a buffer containing 100 mM NaCl, 50 mM Tris-HCl, pH 8.0, 5 mM Na 2 EDTA, 1% Triton X-100, 1% deoxycholic acid, and 50 mM phenylmethylsulfonyl fluoride. The lysate was then incubated overnight at 4Њ with cat anti-FPV serum. Protein A-Sepharose was then added to the antibodylysate mixture and incubated and agitated for 2 hr at room temperature. The complex was washed by centrifugation and finally dissolved and heated for 3 min at 100Њ in loading buffer for a 8-25% SDS-PAGE gradient PhastGel (Pharmacia Biotech, Sweden). After electrophoresis in the Phastsystem Separation and Control Unit, the gel was fluorographed and then exposed to the X-ray film to detect 35 S-labeled proteins. Lanes 1-4 show precipitates from four separate plaque-purified recombinant-infected cell lysates of CV-1 cells infected with RCNV/FPV; protein migrating at 67 kDa is apparent; lane 5 shows lack of a precipitated homolog from a lysate of CV-1 cells infected with RCNV. the protein expressed by RCNV/FPV is structurally satisfactory for appropriate immunogenic determinants of VP2. Consistent with the data here, in a related study, an FPV VP2 monoclonal antibody identified the same expressed VP2 protein in another RCNV construct that coexpresses FPV VP2 and the rabies virus glycoprotein (Hu et al., unpublished data).
The immune response of nine 5-month-old cats to vaccination with the RCNV/FPV was examined by subcutaneous (SQ) inoculation with the recombinant followed by a booster 21 days later. The vaccinated cats and two unvaccinated cats were challenged by using the USDA standard FPV challenge method (28) on Day 34 after primary vaccination. In Fig. 3 we show that following the initial vaccination with RCN/FPV, the geometric mean serum VN antibody titer of the nine vaccinated cats had suggesting that challenge virus replication was stopped by vaccination with RCNV/FPV. On the other hand, unvaccinated animals showed detectable VN titers at Day 5 after FPV challenge. The appearance of circulatory FPV antibodies is consistent with development of a humoral response to infection during challenge. In a separate study (16) with RCNV/FPV at a higher dose in older cats less susceptible to FPV, a single vaccination also showed a significant VN antibody response and protection of cats from FPV challenge.
We have not yet examined the cell-mediated immune response after RCNV/FPV vaccination; however, we speculate that such a response is also playing an active role in providing protection from FPV challenge. In other candidate parvovirus vaccine systems that do not use a recombinant that replicates in the vaccinated animal, e.g., peptide vaccines and baculovirus systems, it is likely that cell-mediated immunity levels are low or not produced.
FIG. 4. Geometric mean of the total white blood cell (WBC) counts
Total white blood cell and differential counts were in peripheral blood samples taken after FPV challenge of vaccinated measured on Days 0, 3, 5, 9, and 20 following FPV chaland nonvaccinated cats. The nine RCNV/FPV vaccinated cats and the lenge. Fig. 4 shows that the nine vaccinated cats had two mock-vaccinated cats challenged with 10 4.7 TCID 50 FPV perorally total white blood cell counts within a normal range of 13 days after booster according to a USDA standard procedure (28). 6.1-21.1 1 10 3 /ml throughout the vaccination and chal-The total and differential WBC were determined from blood samples taken on Days 0, 3, 5, 9, and 20 after challenge. Total WBCs on Day lenge. Also, counts of lymphocytes, monocytes, eosino-0 were considered to be the normal level for the individual cat. The WBC phils, and basophils remained within normal ranges counts were determined using a quantitative automated hematology analyzer (Coulter Counter Model S Plus IV, Coulter Corporation, Hialeah, FL). The dark squares with standard deviation indicate the geometric mean counts of WBCs in the group of nine vaccinated cats. The stippled squares with standard deviation represent the white cell counts in the two mock-vaccinated cats (WBC counts for unvaccinated cats were are similar for cats given standard RCNV in another study not shown). The average of the total WBCs in peripheral blood samples from the nine vaccinated cats and the two unvaccinated cats on the challenge day were considered the normal WBCs. throughout the experimental course. In contrast, the total white cell counts of cats not vaccinated were less than 5 1 10 3 /ml on Days 3 and 9 and were 2.2 1 10 3 /ml on Day 5. Thus, the unvaccinated cats clearly developed panleukopenia, severe lymphopenia, and eosinopenia following FPV challenge. As a typical course of feline panleukopenia, unvaccinated cats had cell counts in the normal range by Day 20 after challenge. We strongly suspect that the RCNV/FPV recombinant 346-354 (1973) . is safe and efficacious for cats because no untoward 10. Jongeneel, C. V., Sahli, R., McMaster, G. K., Hirt, B., J. Virol. 59, effects were apparent during regular examinations of the 564-573 (1986). SQ-vaccinated animals described here. The USDA Stan-11. Tattersall, P., Cawte, P. J., Shatkin, A. J., and Ward, D. C., J. Virol. 20, 273-289 (1976 
